PharmaPath’s commitment to RnD is a key growth driver, firmly connected to our mission and out-licensing business strategy.

Our out-licensing portfolio primarily focuses on our in-house developed dossiers of oral solid dosage forms (immediate and extended release tablets and capsules), allowing Day 1 generic entry for our partners upon patent expiry.

10 Tips For bla bla bla 

bla bla bla bla


Our pharmaceutical development scientists have broad knowledge and expertise and are devoted to developing effective, patent non-infringing generic products of the highest quality.

Our fully integrated development activities range from pre-formulation to formulation and analytical development, scale-up, process validation, stability testing and clinical phase design and execution. We adopt a QbD approach to our product development allowing the implementation of processes that achieve a consistent level of quality and efficiency further supporting our reliable supply.

We are constantly seeking reliable partners in the R&D field to add new products to our portfolio through technology transfer or co-development projects. If you are interested in developing a partnerships with us, please contact us at BD@pharmapath.eu